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Background
Chronic hypoxia is one of the major causes of pulmonary
vascular remodeling associated with right heart hypertro-
phy. Recent studies have indicated that hypoxia upregu-
lates expression of the soluble guanylate cyclase (sGC),
which is activated by the vasodilator nitric oxide (NO).
Thus, using wild type and homozygous endothelial nitric
oxide synthase (NOS3-/-)-knockout mice, we examined
whether activation of sGC by BAY 41-2272 or BAY 58-
2667 could reverse pulmonary vascular remodeling
induced by hypoxia in mice.
Methods and Results
Ten-week-old male wild-type (NOS3+/+) or NOS3-/- mice
were housed under 10% oxygen conditions for 21 or 35
days. In NOS3+/+ mice, hypoxia induced pulmonary
hypertension and pulmonary vascular remodeling, dem-
onstrated by an increase in fully muscularized peripheral
pulmonary arteries. Treatment of mice with the activators
of the sGC, BAY 58-2667 (10 mg/kg d) or BAY 41-2272
(10 mg/kg d), after full establishment of pulmonary
hypertension from day 21 to day 35, reduced right ven-
tricular (RV) systolic pressures (RVSPs), RV weight and
vascular remodeling. In addition, both drugs inhibited
the pressor response to acute hypoxia in the isolated per-
fused lung system. In NOS3-/- mice, only BAY 58-2667
reduced RVSP while both drugs did not reduce RV weight
but significantly reversed muscularization of peripheral
pulmonary arteries.
Conclusions
The present results suggest that activation of sGC reverses
hypoxia-induced pulmonary hypertension and that the
effects on right heart hypertrophy are dependant on
endogenous nitric oxide from endothelial NOS.
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